

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1167)

VOLUNTARY ANNOUNCEMENT

**JACOBIO PRESENTED PRECLINICAL DATA OF PAN-KRAS INHIBITOR
JAB-23E73 AT THE AACR-NCI-EORTC 2025 INTERNATIONAL CONFERENCE
ON MOLECULAR TARGETS AND CANCER THERAPEUTICS**

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company (the “**Shareholders**”) and potential investors about the latest business advancement of the Group.

The board (the “**Board**”) of directors is pleased to announce that, the Company will present the preclinical data of the pan-KRAS inhibitor JAB-23E73 in the form of abstract and poster both titled “Preclinical Investigation of Orally Bioavailable, Potent Pan-KRAS (ON/OFF) Inhibitor JAB-23E73”, during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 (the “**AACR-NCI-EORTC 2025**”) to be held at the Hynes Convention Center in Boston, the United States, from October 22, 2025 to October 26, 2025.

The abstract (no poster) of JAB-23E73 will become available through the conference app beginning at 12 p.m. ET on Wednesday, October 22, 2025, and will also be released as a freely available supplement in the AACR journal, *Molecular Cancer Therapeutics*. The presentation time of the JAB-23E73 poster is 12:30 p.m. – 4:00 p.m. ET, October 23, 2025.

JAB-23E73 is a highly potent and orally bioavailable pan-KRAS (ON/OFF) inhibitor with high selectivity to spare HRAS and NRAS inhibition.

The data shows that JAB-23E73 exhibits superior antitumor activity across multiple cancer types harboring different KRAS driver mutations or amplification. JAB-23E73 induces tumor regression without causing significant body weight change in KRAS-driven mouse tumor models, indicating good tolerability and wide therapeutic window. JAB-23E73 has a favorable PK profile for oral administration, exhibiting plasma concentration-dependent intratumoral p-ERK inhibition. Phase I clinical trials of JAB-23E73 are currently ongoing in both China and the United States for patients with advanced solid tumors harboring KRAS gene alterations (NCT06959615, NCT06973564).

About Jacobio

Jacobio is committed to developing and providing new and innovative products and solutions to improve patients' health. Our pipeline revolves around novel molecular targets on six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our immunostimulatory antibody-drug conjugate (iADC) Platform.

Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that JAB-23E73 will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. Please visit www.jacobiopharma.com for more information.

By Order of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, October 24, 2025

As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Dr. Te-li CHEN as non-executive Director, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.